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Lymphoma Therapy
and Adverse Events

T

Nursing strategies for thinking critically and acting decisively
Amy Goodrich, MSN, CRNP, Nina Wagner-Johnston, MD, and Dana Delibovi, MA, MS

✔

BACKGROUND: Multiple treatment options, com-

bined with disease heterogeneity, have created
nursing challenges in the management of adverse
events (AEs) during antilymphoma therapy. Testing
has revealed that less than half of participating
nurses correctly graded peripheral neuropathy and
neutropenia related to antilymphoma regimens.
OBJECTIVES: This article identifies nursing challeng-

es in the management of AEs associated with therapy for lymphomas and describes how strategies in
critical thinking can help meet those challenges.
METHODS: A comprehensive literature search in

oncology nursing, nursing education, and critical
thinking was conducted; participant responses to
pre- and post-tests at nursing education programs
were evaluated; and a roundtable meeting of
authors was convened.
FINDINGS: Oncology nurses can cultivate critical

thinking skills, practice thinking critically in
relation to team members and patients, leverage
information from the Patient-Reported Outcomes
Common Terminology Criteria for Adverse Events,
and manage workflow to allow more opportunity
for critical thinking.
KEYWORDS
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in recent years (National
Comprehensive Cancer Network [NCCN], 2016c, 2016d). Treatment of
B-cell lymphomas has been enhanced by rituximab (Rituxan®) immunotherapy; novel targeted therapies, such as bortezomib (Velcade®), lenalidomide
(Revlimid®), and idelalisib (Zydelig®); bendamustine (Treanda®) chemotherapy; and other innovations (Coiffier et al., 2002; Fowler et al., 2011, 2014;
NCCN, 2016d; Rummel et al., 2013). Patients with T-cell lymphomas may now
receive histone deacetylase inhibitors and other targeted agents (Duvic et al.,
2009). For patients with Hodgkin lymphoma (HL), although chemotherapy
remains the standard of care, targeted therapies and immunotherapies may
also be indicated as second-line treatment (Ansell et al., 2013; Johnston et al.,
2010; Moskowitz et al., 2015).
A growing number of treatment options, combined with the heterogeneity
of HL and non-Hodgkin lymphoma (NHL), have created nursing challenges in
the management of adverse events (AEs). Nurses are the most trusted healthcare team members (Newport, 2012). This puts the oncology nurse in a strong
position to assess toxicities with the highest level of patient input, to gather information about overall distress related to the toxicities, and to learn how the
toxicities are impacting the patient’s routine activities and daily quality of life.
Nurses are called on to identify a host of AEs in a wide variety of regimens, and
differentiate these AEs from complex lymphoma symptom patterns. Nurses
must then grade each AE accurately, and determine which of the multiple antilymphoma drugs in the regimen may have caused the AE. Finally, nurses must
collaborate with the interdisciplinary care team to recommend whether to adjust therapy based on the grade and description of the AE, distress level, and
impact on quality of life. The recommendation from nurses is essential to help
the patient and clinical team come to a shared decision on therapy adjustment.
These activities require nurses to think critically and act decisively by
conducting a logical and systematic analysis to determine AE grade, deciding
on a recommendation for intervention, and communicating persuasively to
the interdisciplinary team, the patient, and the caregiver (Brenner, Hughes, &
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Sutphen, 2008). This skill set is not limited to lymphoma; it applies
across all types of malignancies. Lymphoma treatment, because
it encompasses so many regimens and virtually all types of AEs,
provides an optimal model for AE management across cancer
care. The problems and solutions presented in this article are applicable to lymphomas but certainly extend beyond lymphoma to
other cancers (see Appendix A).
Nurses can access a number of valuable resources to enhance
their knowledge and competency regarding the assessment and
management of AEs. Among these are guidelines from the NCCN
(2016a, 2016b) on supportive care and the Oncology Nursing
Society’s ([ONS’s], 2016) Putting Evidence Into Practice resources. An overview of all lymphoma treatment toxicities is beyond the
scope of this article but can be found in McFadden, Poniatowski,
and Temple’s (2006) Contemporary Issues in Lymphoma: A Nursing
Perspective and, for more recently introduced regimens, in NCCN
(2016c, 2016d) guidelines for NHL and HL.

symptoms. For example, pruritus and fatigue may occur in HL
and B-cell NHLs, and anemia in diffuse large B-cell lymphoma
(NCCN, 2016c, 2016d).
In this complex setting, inaccurate grading of AEs, uncertainty
or errors in decisions to adjust therapy, and ineffective team communication represent significant hurdles to effective care (Cirillo
et al., 2009; Schulmeister, 2006). Unfavorable outcomes can result, including risks to patient safety (e.g., toxicities graded inaccurately low) and less-optimal treatment efficacy (e.g., drugs are
withheld because of inaccurate high grades on AEs or miscommunication of grade). These hurdles contribute to conditions that
impede critical thinking in nursing practice.

FIGURE 1.

HODGKIN LYMPHOMA AGENTS
APPROVED AGENTS

Challenges

ɔɔ

Lymphoma treatment options are so vast that virtually every possible AE may occur. For example, hematologic toxicities that include anemia, neutropenia, and thrombocytopenia are common
to cytotoxic drugs and molecularly targeted agents. IV doxorubicin (Adriamycin®), cyclophosphamide (Cytoxan®), oral lenalidomide, and numerous other drugs may produce grade 3–4 neutropenia (Baxter Healthcare, 2010; Celgene Corporation, 2015; Pfizer
Laboratories, 2015) Peripheral neuropathy may occur with drugs
as diverse as bortezomib (Velcade®), vincristine (Oncovin®), carboplatin (Paraplatin®), brentuximab vedotin (Adcetris®), alemtuzumab (Lemtrada®), and many more (Genzyme Corporation,
2014; Grisold, Cavaletti, & Windebank, 2012; Millennium
Pharmaceuticals, Inc., 2015; Seattle Genetics, 2015). Serious mucocutaneous reactions are associated with a range of drugs—
from the antibody rituximab to cytotoxic therapy like bendamustine (Genentech, 2014; Teva Pharmaceuticals, 2015). Fatigue and
gastrointestinal (GI) effects are ubiquitous reactions to anticancer therapy (NCCN, 2016a, 2016b), and some injectable drugs,
notably antibodies, carry high risk for hypersensitivity infusion
reactions (Genentech, 2014; Genzyme Corporation, 2014). Older
chemotherapy drugs, which are still heavily relied upon in current
regimens, are characterized by potentially severe and dose-limiting
GI, mucosal, and hematologic AEs.
Because antilymphoma therapy often relies on drug combinations (see Figures 1 and 2), additive or synergistic toxicity
of drugs in the regimen may occur. The introduction of novel
agents into combinations may produce new interactions or toxicities that will not be fully understood without more clinical
experience. The potential exacerbation of toxicities in combination therapy complicates the already intricate set of AEs in
antilymphoma therapy. In addition, various lymphomas have
disease-related symptom patterns that mimic treatment-related
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Bleomycin
Brentuximab vedotin
Carmustine
Chlorambucil
Cyclophosphamide
Dacarbazine
Doxorubicin hydrochloride
Lomustine
Mechlorethamine
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ɔɔ
ɔɔ
ɔɔ
ɔɔ
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Pralatrexate
Prednisone
Procarbazine hydrochloride
Rituximab
Romidepsin
Vinblastine sulfate
Vincristine sulfate
Vorinostat

COMBINATIONS
ɔɔ
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ɔɔ
ɔɔ

ɔɔ
ɔɔ

ɔɔ
ɔɔ

ɔɔ

ɔɔ

ABVE-PC—doxorubicin hydrochloride, bleomycin sulfate, vincristine
sulfate, etoposide, prednisone, cyclophosphamide
BEACOPP—bleomycin sulfate, etoposide phosphate, doxorubicin hydrochloride plus COPP
COPP—cyclophosphamide, vincristine, procarbazine, prednisone
COPP-ABV—COPP plus doxorubicin hydrochloride, bleomycin sulfate,
vinblastine sulfate
ICE—ifosfamide, carboplatin, etoposide
MOPP—mechlorethamine hydrochloride, vincristine sulfate, procarbazine
hydrochloride, prednisone
OEPA—vincristine sulfate, etoposide, prednisone, doxorubicin hydrochloride
OPPA—vincristine sulfate, prednisone, procarbazine hydrochloride,
doxorubicin hydrochloride
Stanford V—mechlorethamine, doxorubicin hydrochloride, vinblastine
sulfate, vincristine sulfate, bleomycin sulfate, etoposide phosphate,
prednisone
VAMP—vincristine sulfate, doxorubicin hydrochloride, methotrexate,
prednisone

Note. Combinations may contain additional chemotherapy drugs in long use for
many types of cancer.
Note. Based on information from National Comprehensive Cancer Network, 2016c.
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FIGURE 2.

NON-HODGKIN LYMPHOMA AGENTS
APPROVED AGENTS
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Alemtuzumab
Belinostat
Bendamustine hydrochloride
Bleomycin
Bortezomib
Brentuximab vedotin
Carmustine
Chlorambucil
Cyclophosphamide
Denileukin diftitox
Dexamethasone

ɔɔ
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Doxorubicin hydrochloride
Ibrutinib
Idelalisib
Interferon
Lenalidomide
Liposomal cytarabine
Mechlorethamine hydrochloride
Methotrexate
Nivolumab
Plerixafor

COMBINATIONS
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
ɔɔ
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ABVD—doxorubicin, bleomycin, vinblastine, dacarbazine
ABVE—doxorubicin, bleomycin, vincristine, etoposide
BR—bendamustine, rituximab
CHOP—cyclophosphamide, doxorubicin, vincristine, prednisone
COPP—cyclophosphamide, vincristine, procarbazine, prednisone
CVP—cyclophosphamide, vincristine, prednisone
EPOCH—etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin
ESHAP—etoposide, methylprednisolone, cytarabine, cisplatin
Hyper-CVAD—cyclophosphamide, vincristine, doxorubicin, dexamethasone
ICE—ifosfamide, carboplatin, etoposide
R-CHOP—rituximab plus CHOP
R-CVP—rituximab plus CVP
R-EPOCH—rituximab plus EPOCH

Note. Combinations may contain additional chemotherapy drugs in long use for
many types of cancer.
Note. Based on information from National Comprehensive Cancer Network, 2016d.

Grading
During lymphoma treatment, nurses confront the documented
challenge of AE grading during assessment and care (Cirillo et al.,
2009; Schulmeister, 2006; Trotti, Colevas, Setser, & Basch, 2007).
Grading inaccuracy can lead to clinical deficits, including underestimation of toxicity and the potential for avoidable risk, as well
as overestimation of toxicity, leading to unnecessary dose reduction or therapy termination. Grading of many AEs include impact
on quality of life, so that the nurse, by making this quality-of-life
assessment, is among the most strongly positioned healthcare
team member to evaluate and report this critical consideration.
Participant responses during 10 nursing education programs,
conducted at ONS Chapters, revealed gaps in grading knowledge
among nurses (Rogers, 2015). An author of the current article
(AG) served as a faculty member for these programs. Program
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participants were presented with six cases and were informed that
the cases pertained to peripheral neuropathy, neutropenia, or infusion reactions. They were asked to identify the symptom or AE,
grade it, and, if appropriate, provide treatment options for that
toxicity and grade. Participant responses were analyzed by an advisor to this article, Barbara Rogers, CRNP, MN, AOCN®, ANP-BC.
Responses revealed that only a minority of participating nurses
could correctly grade the severity of two common AEs in lymphoma therapy—peripheral neuropathy and neutropenia. In another
activity, a higher proportion of participants could correctly grade
infusion reactions, but their ability to grade accurately was far
from universal for this potentially serious AE (see Table 1).
In a blinded survey (Cirillo et al., 2009), nurses graded AEs
more accurately than physicians via the well-established criteria of the Common Terminology Criteria for Adverse Events
(CTCAE) (see Table 2). In the study, accuracy was measured
by the key parameter of patient–clinician agreement (Cirillo
et al., 2009; National Cancer Institute [NCI], 2010; Pakhomov,
Jacobsen, Chute, & Roger, 2008). However, better accuracy did
not always mean higher nurse accuracy. Nurse–patient agreement
in the grading of sensory neuropathy, mucositis, and asthenia was
65% or less by kappa coefficient (KC) (defined as the percentage
by which agreement exceeds that expected by chance). Nurse–
patient agreement was higher for GI AEs (range = 74%KC to 85%KC)
(Cirillo et al., 2009).
Although nurses may exhibit a skill gap in grading AEs, they
display much less of a gap in the identification of AEs. In preand post-testing during the ONS Chapters education programs,
more than 91% of nurses correctly identified peripheral neuropathy, neutropenia, and infusion reaction related to lymphoma
treatment. In addition, survey data show patient–nurse agreement
of 75%KC or greater for identification of six treatment-emergent
AEs—asthenia, nausea, mucositis, sensory neuropathy, constipation, and diarrhea—all of which may occur during one or more
forms of lymphoma therapy (Cirillo et al., 2009).
Barriers to Grading
Undeniably, grading of AEs is difficult. A nurse engaged in grading
is engaged in an analytic process that demands high-level critical
thinking. Several aspects, however, conspire to impair the nurse’s
ability to think critically during grading. The first arises from the
CTCAE itself, which has the potential for incomplete reporting (Trotti et al., 2007). CTCAE is clinician-centric rather than
patient-centric; it does not capture patient self-report of AEs,
severity, or impact. Instead, the CTCAE captures the clinician’s
analysis of laboratory-based events (e.g., blood counts), events
observable on examination (e.g., tremor), and symptomatic events (e.g., nausea) (Basch et al., 2014; Trotti et al., 2007).
However, accruing evidence has shown that patient self-reports of
toxicity are a better gauge of health status than clinician reports,
and that clinicians underreport the severity of AEs in comparison
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TABLE 1.

ACCURACY OF GRADING OF LYMPHOMA THERAPY
ADVERSE EVENTS BY NURSE
CORRECT
PRETEST GRADING
ADVERSE EVENT CASES

n

N

Peripheral neuropathy in
a 65-year-old receiving
R-CHOP for DLBCL

30

130

Neutropenia in a 25-year-old
receiving ABVD for HL

46

Neutropenia in a 40-year-old
receiving BR for FL

%

CORRECT
POST-TEST GRADING
n

N

%

23

49

176

28

110

42

37

137

27

47

107

44

66

138

48

Infusion reaction in a
70-year-old receiving weekly
rituximab for FL

59

115

51

107

160

67

Infusion reaction in an
83-year-old receiving weekly
rituximab for FL

65

114

57

98

156

63

ABVD—doxorubicin, bleomycin, vinblastine, dacarbazine; BR—bendamustine, rituximab;
DLBCL—diffuse large B-cell lymphoma; FL—follicular lymphoma; HL—Hodgkin lymphoma;
R-CHOP—rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Note. Participating nurses completed pre- and post-testing for educational evaluation.
Note. Based on information from Rogers, 2015.

to patients (Basch et al., 2006, 2009, 2014; Brunner et al., 2011;
Dueck et al., 2015; Pakhomov et al., 2008; Quinten et al., 2011). In
other words, the CTCAE may fail to provide the evidence needed
for patient–clinician agreement on AEs, a key measure of grading
validity (Pakhomov et al., 2008). In addition, CTCAE criteria, although in widespread use for decades, have never been formally
validated (Trotti et al., 2007), further compromising CTCAE evidence on the severity of AEs. Because evidence is the input for the
critical thinking process, attaining the output of accurate grading
can be difficult with the current CTCAE.
Another aspect that impedes critical thinking in grading
AEs resides in the language of the CTCAE. Grading verbiage
has changed between CTCAE version 3.0 (NCI, 2006) and the
current version 4.03 (NCI, 2010). Different clinicians may use
different terminology depending on the version with which
they were trained, leading to inconsistent critical analyses. This
problem has been documented for hypersensitivity infusion reactions (DeMoor et al., 2011). A review of 222 cases of hypersensitivity infusion reactions found that different versions of the
grading system led to inconsistencies in grading and clinician
response to the reaction in about 50% of cases (DeMoor et al.,
2011).
The significant weaknesses in the CTCAE has prompted action by the NCI. To overcome the incompleteness and lack of
validation, the NCI has spearheaded the development of the
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Patient-Reported Outcomes CTCAE (PRO-CTCAE) for use in
clinical trials (Basch et al., 2014; Brunner et al., 2011). Although
the PRO-CTCAE has not been adapted for use in community
clinical practice, its validation study did include patients with
lymphoma (Basch et al., 2014), and its implementation in the research setting is instructive for all oncology practitioners.
An additional problem in AE grading is the disjunction between nursing workflow and the critical reasoning process needed
for grading. The nursing day offers little time for this process. An
observational study revealed that frequent task switching and unpredictable demands characterize the nursing workflow (Cornell
et al., 2010; Cornell, Riordan, Townsend-Gervis, & Mobley, 2011).
For example, in an observational study, 68% of nurse tasks on
a pediatric oncology unit were one minute or less in duration
(Cornell et al., 2011). As a result, nurses rarely encounter the
conditions—such as workflow control and uninterrupted time—
needed for critical thinking (Cornell et al., 2010, 2011).
Another issue of concern is nurse visibility and involvement in
the care of patients with lymphoma. The less present and visible
nurses are, the less they are able to gather reports, histories, and
other evidence regarding patients’ AEs. Sustaining a nursing presence requires greater effort than ever because more oral cancer
therapies taken by the patient at home have been introduced for the
treatment of lymphomas (Yagasaki & Komatsu, 2013). Telephonic
assessment is useful for triage of patients and identification of severe AEs but requires experienced clinicians to conduct interviews
and supplementation with face-to-face assessments during scheduled office visits (Kondo et al., 2015; Towle, 2009).
TABLE 2.

COMMON TERMINOLOGY CRITERIA FOR ADVERSE
EVENTS
GRADE

DESCRIPTION

1

Mild; asymptomatic or mild symptoms; clinical or diagnostic
observations only; intervention not indicated

2

Moderate; minimal, local, or noninvasive intervention indicated;
limiting age-appropriate instrumental activities of daily living
(ADLs)a

3

Severe or medically significant but not immediately life-threatening;
hospitalization or prolongation of hospitalization indicated;
disabling; limiting self-care ADLsb

4

Life-threatening consequences; urgent intervention indicated

5

Death related to adverse event

Instrumental ADLs refer to preparing meals, shopping for groceries or clothes, using
the telephone, or managing money.
b
Self-care ADLs refer to bathing, dressing and undressing, feeding self, using the toilet,
taking medications, and not being bedridden.
Note. From Common Terminology Criteria for Adverse Events [v.4.03], by National
Cancer Institute Cancer Therapy Evaluation Program, 2010. Retrieved from http://evs
.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
a
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Lastly, the specific nature of critical thinking itself within the
discipline of nursing can pose problems. Experts in critical thinking in nursing suggest that, for the nurse, critical thinking occurs
within social relationships that involve the patient, caregiver, and
multidisciplinary care team. To think critically in any context,
including the grading of an AE, presupposes insightful, collegial
dialogue and shared observation; the nurse cannot make a critical analysis in isolation (Brenner et al., 2008; Raymond-Seniuk &
Profetto-McGrath, 2011). This raises a question: In a day full of
interruptions and task switching, how can nurses find the time to
exchange ideas with others?
Decision Making
Shared decision making is currently a key model in oncology practice (Clark, Nelson, Valerio, Gong, Taylor-Fishwick, & Fletcher,
2009; Frerichs, Hahlweg, Müller, Adis, & Scholl, 2016). Across
the interprofessional team and between clinicians and patients,
shared decision making is an empowering partnership in care
(Clark et al., 2009). When a clinician shares decision making with
a patient, three supportive roles appear to be most important:
help the patient understand the issue being decided, listen to the
patient’s concerns, and include in discussions what matters most
to the issue (Elwyn et al., 2012; Katz, Belkora, & Elwyn, 2014).

COMMENTARY ON GRADING ADVERSE EVENTS (AEs)

Deborah Watkins Bruner, RN, PhD, FAAN (Advisor)
We have to realize that the [Common Terminology Criteria for Adverse
Events (CTCAE)] has never been validated. So, we actually don’t expect that
if two clinicians graded an AE, there would be inter-grader reliability.
It is also important for nurses to know everything that is—and isn’t—in
the CTCAE. There is no entry for neutropenia in the CTCAE, only entries
for febrile neutropenia and neutrophil count decreased. But prescribing
information for antilymphoma therapies may require adjusting dose for
grades of neutropenia. Nurses have to recognize this disjunction.
Nina Wagner-Johnston, MD (Author)
In many lymphoma subtypes, our goal from the outset is cure. That means
we want high dose intensity. We don’t want to be reducing or holding
the dose for toxicity if it isn’t necessary. That’s why getting an accurate
grade and description of an AE is so important. It’s also why we need good
communication of the grade and description of the AE, to ensure that any
dose modifications are based on vetted, analyzed evidence.
Amy Goodrich, MSN, CRNP (Author)
CTCAE grading has flaws, but it still enhances communication between
clinicians by giving us a similar language. But you don’t just call a physician and say “grade 2 toxicity” and then drop it. You have to explain that
toxicity, its features, and why it is important to manage it in this patient.
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“Nurses have cited
a lack of critical
thinking as one
of the top five most
likely causes of
nursing errors.”
Shared decision making may be impeded by limitations to critical
thought. For example, some patients are reluctant to share decision
making because they engage in “counterfactual thinking,” meaning
that they may anticipate feeling regret or self-recrimination if they
share in a decision, like stopping a particular drug related to AEs
and then, months or years later, experience disease progression
(Katz et al., 2014). When nurses have difficulty recognizing and
analyzing such reasoning, they may be unable to fully empower
the patient as a decision maker.
Within the context of shared decision making, the nurse may
be called on to offer evidence, in the form of AE grading and narrative description, with critical consideration of quality of life and
distress related to the AE. With this information, the nurse helps
the patient participate in the decision to hold treatment or reduce
the dose. With systemic therapies, the development of a toxicity and establishing its grade typically determines the decision to
continue, reduce, or hold treatment. For example, the decision to
reduce bortezomib dose from 1.3 mg/m2 to 1 mg/m2 in mantle-cell
lymphoma requires precision in grading. If a patient has grade 1
neuropathy with no impact on quality of life and no pain, then no
bortezomib dose adjustment is required. However, grade 2 neuropathy with pain (with limitations on instrumental activities of daily
living) and grade 3 neuropathy (limitations on self-care activities of
daily living) require holding bortezomib until the neurologic toxicity resolves (Millennium Pharmaceuticals, Inc., 2015; NCI, 2010).
Misgrading could produce dosing or treatment error.
Medication errors are not uncommon, including giving the
wrong dose and giving a dose after a discontinuation order (Ford,
Killebrew, Fugitt, Jacobsen, & Prystas, 2006). Nurses attribute errors to factors that unfavorably influence critical thinking (Cornell
et al., 2010, 2011), such as adding tasks to the workload, chaos in the
work environment, being swamped or overwhelmed, emotional responses, and a loss of focus (Roth, Wieck, Fountain, & Haas, 2015;
Valiee, Peyrovi, & Nasrabadi, 2014). Of note, nurses themselves
have cited a lack of critical thinking as one of the top five most
likely causes of nursing errors in the hospital (Roth et al., 2015).

CJON.ONS.ORG

Communication
Even when AEs are graded accurately, communication of the
grade and recommended approaches can pose challenges.
Barriers to effective communication may result from deficits in
critical thinking relevant to managing AEs in lymphoma. These
deficits include the following:
ɐɐ Lack of reasoning across relationships—an inability to understand, anticipate, and compensate for the types of errors
that may occur between patient report, upload to the medical record, interpretation and CTCAE grading, and subsequent team discussion. These errors can include gaps in
communication; loss of shared interpretation of symptoms among
professionals, patients, and caregivers (link loss); and recording
and documentation errors (Basch et al., 2005) (see Figure 3).
ɐɐ Problems in evidence processing—keeping up with new toxicities
when a novel therapy or regimen is introduced in the already complex care of lymphoma (e.g., diarrhea and cough with idelalisib in
follicular lymphoma) is challenging (Coutré et al., 2015).
ɐɐ Using a terse or incomplete narrative to describe an AE, which
does not take into account the listener’s need for evidence—
for example, communicating grade only by the number, rather than also describing its clinical features. An example of this
would be writing or saying only “grade 3 fatigue” with lenalidomide without providing information on the patient’s inability
to find relief with rest, specific limitations in daily activities,
and how well the patient is coping (Celgene Corporation, 2015;

NCI, 2010); incomplete narrative also means that a nurse may
not have documented the details needed to trigger accurate
grading.
ɐɐ Lack of curiosity and self-reflection limits the ability to ask
questions, solicit feedback, and identify misunderstandings.

Improving Practice: Tools for Thinking Critically
and Acting Decisively
The nursing community has been an important contributor in
education to improve critical thinking (Delibovi, 2015). Oncology
nurses can use the guidance of nurse educators to enhance critical thinking to improve accuracy in the grading of AEs, to increase
precision and confidence in recommendations for the adjustment
of therapy, and to communicate recommended approaches clearly
and convincingly to aid in the process of shared decision making.
Cultivating Critical Thinking Skills
The nursing literature has identified several important skills
for critical thinking among nurses (Brenner et al., 2008;
Papathanasiou, Kleisaris, Fradelos, Kakou, & Kourkouta, 2014:
Papp et al., 2014; Phelps et al., 2009; Raymond-Seniuk & ProfettoMcGrath, 2011):
ɐɐ Flexibility—the ability to remain curious, to ask questions, to
stay alert for unexpected circumstances, and to alter preconceived notions on the basis of observations
ɐɐ Willingness to analyze situations and statements deeply

FIGURE 3.

POTENTIAL REDUCTION OF LINK LOSS AND DATA ENTRY ERRORS WITH DIRECT COLLECTION
OF PATIENT-REPORTED SYMPTOM
Clinician interviews patient
Patient
experience of
symptom

Clinician writes in chart
Clinician
interpretation
of symptom

Clinician-reported outcomes: Traditional paradigm
Patient-reported outcomes: Investigational paradigm
Patient
experience of
symptom

RA reads chart
Chart
representation
of symptom

Interpretation
of symptom
by the RA

RA data entry

Research database
record of symptom

Patient enters errors directly into database

RA—research assistant
Note. From "Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy," by E. Basch, D. Artz, D. Dulko, K. Scher, P. Sabbatini, M. Hensley, . . . D. Schrag, 2005, Journal of
Clinical Oncology, 23, p. 3553. Copyright 2005 by American Society of Clinical Oncology. Reprinted with permission.
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ɐɐ A systematic and orderly approach to all decision making, including a consistent methodology and use of evidence to support decisions
ɐɐ A focus on problem solving
ɐɐ The ability to expect, understand, and embrace differences in
perspective between oneself and other people
ɐɐ Self-reflectiveness and the ability to admit error and uncertainty.
These skills are highly relevant to best practices in the process
of AE grading, decision making, and communicating in antilymphoma therapy (see Figure 4). For example, even a simple best
practice, such as comparing a blood count or a report of neuropathy to the actual text of the CTCAE, cannot be fully actualized
without critical thinking. The reason is that patient data and best
practices qualify as what nurse educators term "messy information" (Rowles, Morgan, Burns, & Merchant, 2013). Patient data
can be scattered, fragmented, or incomplete. Best practices may
be gathered from various potentially conflicting sources, such as
cancer center memos, published guidelines, first-person articles
by experts, facility medical directors, and even third-party payors.

FIGURE 4.

SELECTED BEST PRACTICES IN ADVERSE EVENT
(AE) GRADING, DOSE ADJUSTMENT, AND
COMMUNICATION
ɔɔ

ɔɔ

ɔɔ

ɔɔ

ɔɔ

ɔɔ

ɔɔ

ɔɔ

ɔɔ

Recognize that errors can occur; anticipate that identification and grading
of AEs can be difficult, particularly in complex lymphoma regimens.
Obtain patient self-reports of symptoms at every interaction, using formal
assessment tools when available; document self-reports carefully (including patient’s reports verbatim).
Use outreach methods to sustain nursing visibility, particularly in patients
taking oral antilymphoma therapies at home; methods include telephonic
follow-up, email, and patient web portals.
Routinely review AE sections of prescribing information for all agents that
the patient receives.
Consult Common Terminology Criteria for Adverse Events (CTCAE) regularly to harmonize documentation with standard grading terminology;
post in the nurse’s station or wherever documentation takes place.
Compare laboratory results and patient reports to the actual entry in the
CTCAE; do not rely on memory of the CTCAE when grading, particularly
for numeric criteria, such as neutrophil counts.
Write or verbalize for the team a clear, full, narrative description, along
with CTCAE grade, of every AE that may need intervention.
Never give or accept verbal orders for dose adjustments; make written
orders standard.
Double check dose modifications and supportive care decisions with
pharmacy.

Note. Based on information from Basch et al., 2009; Jacobsen et al., 2009;
Schulmeister, 2006; Yagasaki & Komatsu, 2013.
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Often, no guidance may exist on how to apply a best practice to a
particular patient scenario.
What should be done, for instance, if a patient reports trouble
buttoning his shirt, but is unable to answer most of the symptomfocused questions on the cancer center’s peripheral neuropathy
assessment tool? To solve this problem, a nurse might analyze the
patient’s report deeply, reach out once more to the patient for additional evidence of neuropathy, and try to understand the difference between the clinical perspective and the patient’s perspective on his symptoms—three of the critical thinking skills cited
earlier in this article. Therefore, to follow best practices, critical
thinking is required to assimilate and use the messy information
pertinent to each case (Rowles et al., 2013).
Critical Thinking in Relationship
Considering the perspectives of others is a particularly meaningful part of the nursing skill set (Papp et al., 2014; Raymond-Seniuk
& Profetto-McGrath, 2011). Part of the definition of a challenged
thinker, a nurse who struggles to think critically, is resistance to
consideration of others’ perspectives (Papp et al., 2014). The effort to “think in relationship” has profound and positive effects on
communication regarding AEs and adjustment of therapy. When
explaining an AE or recommending a dose adjustment, it matters
who receives the explanation or recommendation. Depending on
prior experience, healthcare professionals, patients, and caregivers may have different levels of familiarity with grading schema.
Therefore, when communicating with different individuals, the
nurse cannot assume that writing or saying “grade 3 sensory neuropathy” will be sufficient. To take into account others’ perspectives, a statement of the grade should be accompanied by a narrative description of the AE that include features, such as onset,
location, and duration; conditions that worsen or alleviate the AE;
the nature of the symptoms; severity; and interference with quality
of life. Nurses may even want to create a template or reminder to
include these features that functions as a verbal or written script
for communication. Scripting is a technique borrowed from successful nursing education for critical thinking (Su & Juestel, 2010),
and it may be a useful tool in clinical practice as well.
In antilymphoma therapy, a key aspect of the patient–nurse
relationship, nursing presence, has become more challenging.
Challenges to nurse visibility stem from the growing number of
oral, self-administered therapies available (Yagasaki & Komatsu,
2013), including approved therapies such as lenalidomide (mantlecell lymphoma), vorinostat (cutaneous T-cell lymphoma), idelalisib (follicular lymphoma, small lymphocytic lymphoma), and
others (Celgene Corporation, 2015; Gilead Sciences, 2014; Merck
Sharp & Dohme Co., 2015). When patients receive oral antilymphoma therapy, “thinking in relationship” is an important
nursing skill that involves understanding the perspective of the
patient at home. This patient may be hesitant to make a call to
report an AE, may forget the importance of watching for AEs, or

CJON.ONS.ORG

IMPLICATIONS FOR PRACTICE
ɔɔ

may generally feel more distant from the nurse. Understanding
the patient’s perspective in such cases can prompt nurses to
make more frequent and vigorous outreach by phone or email or
on the occasion of a visit to the cancer center.
Leverage Learning From the PRO-CTCAE
The patient-centric PRO-CTCAE has been shown to be valid, reliable, and responsive, indicating that its patient-centeredness
is an asset (Dueck et al., 2015). It also is designed to help minimize communication gaps, link loss, and problems in recording
error (Basch et al., 2005, 2014). PRO-CTCAE use is gaining momentum in the clinical trial setting, but is not yet widely used
in clinical care.
Questions posed to patients via the PRO-CTCAE were designed with three features: plain language terminology for the
symptom; a focus on eliciting frequency, severity, and interference

FIGURE 5.

PRO-CTCAE STAKEHOLDERS RATING
OF PATIENT-REPORTED OUTCOMES IN
ADVERSE EVENT ASSESSMENT (N = 727)
100

STAKEHOLDERS IN AGREEMENT (%)

90

80

70

60

50
PR1

PR2

PR3

PR4

PATIENT REPORTS OF IMPROVEMENT
PR1—useful to improve understanding of patient experience; PR2—improved
completeness of symptom data collection; PR3—improved accuracy of symptom data collection; PR4—improved efficiency of symptom data collection;
PRO-CTCAE—Patient-Reported Outcomes Common Terminology Criteria for
Adverse Events
Note. Based on information from Brunner et al., 2011.
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ɔɔ

ɔɔ

Understand that a growing number of treatment options, combined
with the heterogeneity of Hodgkin and non-Hodgkin lymphomas,
have created nursing challenges in the management of adverse
events (AEs).
Prepare for challenges regarding accurate grading, shared
decision making in the adjustment of therapy based on grade, and
communication of action plans to the interdisciplinary team and
the patient.
Meet these challenges by developing critical thinking skills, thinking
in relation to recognize the perspectives of others, leveraging information from patient-reported outcomes for AEs, and managing
workflow to facilitate critical thinking.

with activity from the patient; and a mechanism to gather the recall period for the symptom (Basch et al., 2014). Sample question
formats include: “In the past, how OFTEN did you have [symptom]?”; “In the past, what was the SEVERITY of your [symptom]
at its worst?”; “In the past, how much did [symptom] INTERFERE
with your usual or daily activities?” (Basch et al., 2014, p. 1). Data
have shown a strong consensus among key stakeholders in the implementation of the PRO-CTCAE that including patient reporting
of adverse symptoms would be useful for improving understanding of the patient experience in a cancer clinical trial (Brunner et
al., 2011). In addition, a high proportion of stakeholders endorsed
administration of PRO-CTCAE clinical trials to improve completeness, accuracy, and efficiency of AE data collection (Brunner
et al., 2011) (see Figure 5). These findings may suggest that nurses
in community clinical practice may gather better input for critical
analysis of CTCAE grade by asking patients to describe their own
experience of frequency, severity, and interference with an AE, potentially leading to more accurate grading.
Manage Workflow
Chaos and task switching are part of the nursing day, but they
are not conducive to the critical thinking needed for accurate
grading, confident decision making on the adjustment of therapy,
and well-organized communication (Cornell et al., 2010, 2011).
Interventions to improve workflow may have a positive impact on
critical thinking (Cornell et al., 2011). These include methods that
nurses can deploy themselves, such as seeking out education on
time and workflow management, delegation of routine or repetitive tasks to non-nursing staff, and more skillful and systematic
use of technology (Cornell et al., 2011). Other methods must be
championed at the institutional level, such as workflow evaluation and redesign, implementation of better software systems,
and reallocation of duties (Cornell et al., 2011).

Conclusion
In antilymphoma therapy, proper management of AEs is essential to good clinical outcomes. The response to AEs cannot
be optimal without precise grading of toxicities, adjustment of
therapy based on grade and AE description, and effective interdisciplinary and patient–clinician communication. Building
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nursing competency in these areas requires development of
critical thinking, which enables nurses to implement best practices decisively and appropriately in each clinical case.
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APPENDIX A.

CASE STUDY: CRITICAL THINKING SKILLS AND METHODS FOR ORAL MUCOSITIS
SETTING

K.L. is an oncology nurse in a suburban group practice with an infusion center.
The patient, M.G., is a 60-year-old man newly diagnosed with follicular lymphoma who is receiving six planned cycles of bendamustine and rituximab (BR).
PERSPECTIVE TAKING, LEVERAGING THE PRO-CTCAE

M.G. said that he hates to bother people with his problems. Because K.L. considers M.G.’s perspective, she always asks him specific questions about symptoms
while reassuring him that his problems are important to the team. During a
call three days before the last of M.G.’s six BR cycles, K.L.’s question, "Are you
feeling anything that interferes with your daily life?" prompts M.G. to say that his
mouth is so sore that he does not want to eat and cannot eat anything crunchy.
More discussion reveals a symptom pattern commensurate with oral mucositis
(stomatitis). K.L. asks M.G. to come in for an examination, and she and the
physician document visible redness and a small sore on the tongue. K.L. asks
the physician and another nurse on the team to confirm orders for self-care (ice
chips, soft food) and topical treatment.
SYSTEMATIC APPROACH TO SHARED DECISION MAKING AND
WORKFLOW MANAGEMENT

In preparation for a team meeting, K.L. uses her 20 minutes of daily planning
time, which she specifically requested from her employers, to chart the information on M.G.’s reported symptoms. She compares her learnings to the CTCAE
and determines that she needs more information: (a) the nature of mouth
irritation with rituximab versus bendamustine and (b) how much mouth pain, on
a scale of 1–10, M.G. is experiencing. K.L. checks the prescribing information for
the two drugs and telephones M.G. to obtain his numeric pain rating.
PERSPECTIVE TAKING, FOCUS ON PROBLEM SOLVING, WILLINGNESS
TO ANALYZE DEEPLY

Several others at the meeting, including M.G.’s physician and the practice manager, need more information than just the CTCAE grade. For this reason, K.L. has
notes for a narrative description:
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Based on phone interviews, M.G. has grade 3 oral mucositis, graded in this
way because of interference with oral food intake and pain of moderate to
severe intensity, measured as 6 on a 10-point pain scale.
ɔɔ Symptoms have been present and increasing gradually for four weeks.
ɔɔ The most likely cause is bendamustine chemotherapy, but rituximab can
cause mucocutaneous reactions as well.
The physician notes that the prescribing information for bendamustine
regarding stomatitis does not specify when to hold or decrease the dose for
this AE. Another nurse on the team, as well as the practice manager, share this
experience: In another case of grade 3 oral mucositis where the patient was
very far along in bendamustine treatment, the team gave the final cycle of the
chemotherapy with no dose reduction while continuing to provide self-care
methods and topical treatment to control the pain and irritation.
The team decides to recommend this approach, and K.L. discusses it with M.G.
when he arrives for his treatment. K.L., in concert with the physician, presents
the team’s reasoning process and supporting evidence. M.G. expresses a wish
not to hold the last dose chemotherapy; he wants to complete his cycles and
notes that self-care in the past few days has already helped. M.G. shares in the
decision to go ahead with the last cycle of BR.
ɔɔ

FLEXIBILITY AND ABILITY TO ADMIT UNCERTAINTY

After the treatment, M.G.’s physician contacts K.L. and the practice manager
to offer a caveat: Because rituximab has not been completely ruled out as a
cause, M.G.’s symptom pattern should be followed telephonically for a number
of weeks after this last BR treatment. This is recommended because mucocutaneous reactions to rituximab can signal serious adverse events, such as
Stevens-Johnson syndrome, and require discontinuation. K.L. agrees to provide
this follow up.
PRO-CTCAE—Patient-Reported Outcomes Common Terminology Criteria for Adverse
Events
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